Filter by: patients
What is Emtricitabine (FTC)?

Emtricitabine is a nucleoside reverse transcriptase inhibitor used in the treatment of HIV infection in combination with at least two other antiretroviral agents. Off label it is used for Hepatitis B (with HIV coinfection).

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
HIV (Human Immunodeficiency Virus) 9 2 Efficacy_major Efficacy_moderate
General health 1 0
Participate in clinical trial 1 1 Efficacy_moderate

See all 11 patients currently taking Emtricitabine (FTC)

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
1
Mild
1
None
1

Commonly reported side effects, conditions, and hospitalizations associated with Emtricitabine (FTC)

Diarrhea 1
Cramps in stomach 1

Reported Dosages

  1 mg daily 200 daily 200 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 8 Number of Patients: 8  

Reported Stop Reasons

Why Patients Stopped Taking Emtricitabine (FTC) (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped taking Emtricitabine (FTC)

Currently Taking Emtricitabine (FTC)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Emtricitabine (FTC)

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Emtricitabine (FTC)

Always
2 67%
Usually
1 33%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Emtricitabine (FTC)

Very
0 0%
Somewhat
1 33%
A little
0 0%
Not at all
2 67%

Cost

Paid out of pocket

Cost of Emtricitabine (FTC)

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 33%
< $25
2 67%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 11, 2012.